Multivariate analysis of factors affecting OS
| Multivariate (model 1) . | P . | HR (95% CI) . |
|---|---|---|
| Mayo 2004 staging with European modification | ||
| Mayo 2004 stage 1 | Ref | |
| Mayo 2004 stage 2 | .559 | 1.178 (0.68-2.038) |
| Mayo 2004 stage 3a | .001 | 2.302 (1.387-3.822) |
| Mayo 2004 stage 3b | .011 | 2.327 (1.217-4.449) |
| Combined hematologic response and FLC-MS status | ||
| 12mo CR and FLC-MS negative | Ref | |
| 12mo CR and FLC-MS positive | .021 | 3.576 (1.214-10.529) |
| 12mo VGPR and FLC-MS negative | .012 | 5.079 (1.421-18.155) |
| 12mo VGPR and FLC-MS positive | .001 | 6.068 (2.173-16.945) |
| 12mo PR/NR | <.0001 | 9.507 (3.469-26.058) |
| Multivariate (model 2) | ||
| Mayo 2012 staging | ||
| Mayo 2012 stage 1 | Ref | |
| Mayo 2012 stage 2 | .47 | 1.299 (0.639-2.639) |
| Mayo 2012 stage 3 | .02 | 2.223 (1.131-4.367) |
| Mayo 2012 stage 4 | .006 | 2.57 (1.31-5.044) |
| Creatinine∗ | .01 | 2.263 (1.213-4.219) |
| Combined hematologic response and FLC-MS status | ||
| 12-mo CR and FLC-MS negative | Ref | |
| 12-mo CR and FLC-MS positive | .097 | 2.517 (0.847-7.481) |
| 12-mo VGPR and FLC-MS negative | .125 | 2.823 (0.75-10.616) |
| 12-mo VGPR and FLC-MS positive | .005 | 4.476 (1.586-12.632) |
| 12-mo PR/NR | <.001 | 6.356 (2.303-17.538) |
| Multivariate (model 1) . | P . | HR (95% CI) . |
|---|---|---|
| Mayo 2004 staging with European modification | ||
| Mayo 2004 stage 1 | Ref | |
| Mayo 2004 stage 2 | .559 | 1.178 (0.68-2.038) |
| Mayo 2004 stage 3a | .001 | 2.302 (1.387-3.822) |
| Mayo 2004 stage 3b | .011 | 2.327 (1.217-4.449) |
| Combined hematologic response and FLC-MS status | ||
| 12mo CR and FLC-MS negative | Ref | |
| 12mo CR and FLC-MS positive | .021 | 3.576 (1.214-10.529) |
| 12mo VGPR and FLC-MS negative | .012 | 5.079 (1.421-18.155) |
| 12mo VGPR and FLC-MS positive | .001 | 6.068 (2.173-16.945) |
| 12mo PR/NR | <.0001 | 9.507 (3.469-26.058) |
| Multivariate (model 2) | ||
| Mayo 2012 staging | ||
| Mayo 2012 stage 1 | Ref | |
| Mayo 2012 stage 2 | .47 | 1.299 (0.639-2.639) |
| Mayo 2012 stage 3 | .02 | 2.223 (1.131-4.367) |
| Mayo 2012 stage 4 | .006 | 2.57 (1.31-5.044) |
| Creatinine∗ | .01 | 2.263 (1.213-4.219) |
| Combined hematologic response and FLC-MS status | ||
| 12-mo CR and FLC-MS negative | Ref | |
| 12-mo CR and FLC-MS positive | .097 | 2.517 (0.847-7.481) |
| 12-mo VGPR and FLC-MS negative | .125 | 2.823 (0.75-10.616) |
| 12-mo VGPR and FLC-MS positive | .005 | 4.476 (1.586-12.632) |
| 12-mo PR/NR | <.001 | 6.356 (2.303-17.538) |
Model 1 is based on Mayo staging 2004 with European modification, dFLC at baseline, creatinine, and the combined hematologic and FLC-MS response at 12 months. Creatinine and dFLC were found not to be significant on multivariate Cox regression analysis. Model 2 is based on the Mayo 2012 staging, creatinine, and the combined hematologic and FLC-MS response at 12 months.
eGFR, estimated glomerular filtration rate; Ref, reference.
Log10 transformation.